This company has been marked as potentially delisted and may not be actively trading.

Day One Biopharmaceuticals (DAWN) Financials

Annual Income Statements for Day One Biopharmaceuticals

This table shows Day One Biopharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-13	-41	0.00	0.00	0.00	0.00	0.00
Consolidated Net Income / (Loss)	-17	-44	0.00	0.00	0.00	0.00	0.00
Net Income / (Loss) Continuing Operations	-17	-44	0.00	0.00	0.00	0.00	0.00
Total Pre-Tax Income	-17	-44	0.00	0.00	0.00	0.00	0.00
Total Operating Income	-15	-14	0.00	0.00	0.00	0.00	0.00
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	15	14	0.00	0.00	0.00	0.00	0.00
Selling, General & Admin Expense	1.01	4.68	0.00	0.00	0.00	0.00	0.00
Research & Development Expense	14	9.10	0.00	0.00	0.00	0.00	0.00
Total Other Income / (Expense), net	-2.08	-30	0.00	0.00	0.00	0.00	0.00
Interest & Investment Income	-	0.00	0.00	0.00	0.00	0.00	0.00
Other Income / (Expense), net	-0.00	-30	0.00	0.00	0.00	0.00	0.00
Income Tax Expense	-	-	0.00	0.00	0.00	0.00	0.00
Basic Earnings per Share	($2.13)	($7.33)	$0.00	$0.00	$0.00	$0.00	$0.00
Weighted Average Basic Shares Outstanding	5.92M	5.53M	0.00	0.00	0.00	0.00	0.00
Diluted Earnings per Share	($2.13)	($7.33)	$0.00	$0.00	$0.00	$0.00	$0.00
Weighted Average Diluted Shares Outstanding	5.92M	5.53M	0.00	0.00	0.00	0.00	0.00
Weighted Average Basic & Diluted Shares Outstanding	5.92M	5.53M	36.96M	73.59M	87.38M	101.35M	103.30M

This table shows Day One Biopharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-46	-46	-55	-62	-4.41	37	-99	-36	-30	-20	-21
Consolidated Net Income / (Loss)	-46	-46	-55	-62	-4.41	37	-66	-36	-30	-20	-21
Net Income / (Loss) Continuing Operations	-46	-46	-55	-62	-4.41	37	-66	-36	-30	-20	-21
Total Pre-Tax Income	-46	-46	-55	-62	-2.86	36	-59	-36	-30	-20	-23
Total Operating Income	-49	-51	-60	-67	-115	30	-65	-41	-35	-24	-27
Total Gross Profit	0.00	0.00	-	0.00	8.19	92	26	28	34	40	42
Total Revenue	0.00	0.00	-	0.00	8.19	94	29	31	34	40	54
Operating Revenue	-	-	-	0.00	8.19	94	-	31	34	40	54
Total Cost of Revenue	0.00	0.00	-	0.00	0.00	1.59	2.98	2.88	0.00	0.00	12
Total Operating Expenses	49	51	60	67	123	63	92	69	69	64	69
Selling, General & Admin Expense	17	18	22	27	30	29	30	29	29	28	34
Research & Development Expense	32	33	37	40	92	34	62	40	36	31	41
Total Other Income / (Expense), net	3.39	5.29	5.05	4.36	112	6.52	6.09	5.07	4.65	4.53	4.20
Interest & Investment Income	3.41	5.29	5.02	4.37	112	5.32	6.05	5.09	4.67	4.56	4.15
Other Income / (Expense), net	-0.02	-0.00	-	-0.01	-0.01	1.20	0.04	-0.02	-0.02	-0.03	0.06
Income Tax Expense	0.00	0.00	-	0.00	1.55	-0.88	-	0.00	0.00	0.00	-1.98
Basic Earnings per Share	($0.61)	($0.54)	($0.63)	($0.72)	($0.05)	$0.38	($0.63)	($0.35)	($0.29)	($0.19)	($0.21)
Weighted Average Basic Shares Outstanding	74.96M	85.95M	79.77M	86.68M	87.12M	96.62M	93.23M	102.71M	103.07M	103.38M	103.21M
Diluted Earnings per Share	($0.61)	($0.54)	($0.63)	($0.72)	($0.05)	$0.38	($0.63)	($0.35)	($0.29)	($0.19)	($0.21)
Weighted Average Diluted Shares Outstanding	74.96M	85.95M	79.77M	86.68M	87.12M	96.94M	93.23M	102.71M	103.07M	103.38M	103.21M
Weighted Average Basic & Diluted Shares Outstanding	86.97M	87.04M	87.38M	87.39M	87.76M	100.85M	101.35M	101.36M	102.43M	102.68M	103.30M

This table details how cash moves in and out of Day One Biopharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	26	16	-72,754	-142,181	-188,917	-95,496	-107,322
Net Cash From Operating Activities	-4.52	-13	-72,754	-142,181	-188,917	-95,496	-107,322
Net Cash From Continuing Operating Activities	-4.51	-13	-72,754	-142,181	-188,917	-95,496	-107,322
Net Income / (Loss) Continuing Operations	-17	-44	-72,754	-142,181	-188,917	-95,496	-107,322
Consolidated Net Income / (Loss)	-17	-44	-72,754	-142,181	-188,917	-95,496	-107,322
Net Cash From Investing Activities	0.00	-0.09	0.00	0.00	0.00	0.00	0.00
Net Cash From Continuing Investing Activities	0.00	-0.09	0.00	0.00	0.00	0.00	0.00
Net Cash From Financing Activities	31	30	0.00	0.00	0.00	0.00	0.00
Net Cash From Continuing Financing Activities	31	30	0.00	0.00	0.00	0.00	0.00

This table details how cash moves in and out of Day One Biopharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	140	52	-10	40	-31	183	-298	-92	2.26	7.66	154
Net Cash From Operating Activities	-42	-37	-41	-50	-49	51	-30	-59	-25	-5.81	-14
Net Cash From Continuing Operating Activities	-42	-37	-41	-50	-49	51	-30	-59	-25	-5.81	-14
Net Income / (Loss) Continuing Operations	-46	-46	-55	-62	-4.41	37	-66	-36	-30	-20	-21
Consolidated Net Income / (Loss)	-46	-46	-55	-62	-4.41	37	-66	-36	-30	-20	-21
Depreciation Expense	0.01	0.01	0.01	0.02	0.02	0.02	0.04	0.09	0.09	0.09	0.09
Amortization Expense	-5.17	-2.56	-1.49	-1.20	-0.50	-0.65	-2.10	-3.45	-3.28	-3.28	-2.31
Non-Cash Adjustments To Reconcile Net Income	9.48	12	11	13	-95	67	11	13	11	9.56	11
Changes in Operating Assets and Liabilities, net	-0.88	-0.68	3.50	1.32	51	-52	27	-33	-2.27	7.55	-1.72
Net Cash From Investing Activities	20	89	30	89	17	-68	-270	-33	26	13	167
Net Cash From Continuing Investing Activities	20	89	30	89	17	-68	-270	-33	26	13	167
Purchase of Investments	-105	-80	-99	-47	-122	-215	-275	-190	-239	-210	-58
Sale and/or Maturity of Investments	125	172	130	136	48	203	7.00	161	265	223	225
Net Cash From Financing Activities	162	0.12	0.60	0.05	1.30	200	1.85	0.00	0.75	-	0.47
Net Cash From Continuing Financing Activities	162	0.12	0.60	0.05	1.30	200	1.85	0.00	0.75	-	0.47
Issuance of Common Equity	162	-	0.60	-	0.97	199	0.93	-	-	-	0.35
Other Financing Activities, net	0.04	0.12	-	0.05	0.32	0.98	0.92	0.00	-	-	0.13
Cash Income Taxes Paid	-	-	-	-	-	-	1.02	-	-	-	-0.57

This table presents Day One Biopharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	46	290	349	376	583	508
Total Current Assets	45	289	348	375	562	485
Cash & Equivalents	44	284	85	231	125	197
Short-Term Investments	-	0.00	257	136	407	244
Accounts Receivable	-	-	-	0.00	14	27
Inventories, net	-	-	-	0.00	3.32	6.33
Prepaid Expenses	1.34	5.06	5.61	8.93	13	11
Plant, Property, & Equipment, net	0.08	0.06	0.02	0.21	2.29	2.14
Total Noncurrent Assets	0.51	0.23	1.17	0.57	18	21
Intangible Assets	-	-	-	0.00	16	18
Other Noncurrent Operating Assets	0.51	0.23	1.17	0.57	2.54	2.57
Total Liabilities & Shareholders' Equity	46	290	349	376	583	508
Total Liabilities	2.20	8.67	17	30	80	67
Total Current Liabilities	2.00	8.66	17	30	73	61
Accounts Payable	0.20	1.74	0.26	2.58	3.26	3.73
Accrued Expenses	1.60	6.71	16	27	69	55
Current Deferred Revenue	-	-	-	0.00	1.55	2.00
Other Current Liabilities	0.20	0.20	0.41	0.41	0.01	0.17
Total Noncurrent Liabilities	92	0.02	0.41	0.00	6.59	6.14
Noncurrent Deferred Revenue	-	-	-	0.00	3.23	3.04
Other Noncurrent Operating Liabilities	92	0.02	0.41	0.00	3.35	3.10
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-55	281	332	347	503	441
Total Preferred & Common Equity	-54	281	332	347	503	441
Total Common Equity	-55	281	332	347	503	441
Common Stock	2.00	409	602	805	1,057	1,103
Retained Earnings	-57	-127	-270	-459	-554	-661
Accumulated Other Comprehensive Income / (Loss)	-	0.00	-0.07	0.01	0.08	0.07

This table presents Day One Biopharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	382	324	451	414	327	400	601	534	519	514
Total Current Assets	381	645	450	413	326	383	581	509	494	490
Cash & Equivalents	121	49	189	241	270	240	423	33	36	43
Short-Term Investments	253	269	254	164	48	122	136	440	417	408
Accounts Receivable	-	-	-	-	-	9.14	8.70	18	20	17
Inventories, net	-	-	-	-	-	0.15	2.74	3.57	6.54	7.06
Prepaid Expenses	6.17	4.21	6.90	7.75	8.09	12	11	14	15	15
Plant, Property, & Equipment, net	0.04	0.07	0.18	0.21	0.19	0.20	0.90	2.51	2.32	2.23
Total Noncurrent Assets	1.31	1.10	0.79	0.68	0.26	17	19	23	22	22
Intangible Assets	-	-	-	-	-	17	16	20	20	19
Other Noncurrent Operating Assets	1.31	1.10	0.79	0.68	0.26	0.16	2.69	2.79	2.68	2.77
Total Liabilities & Shareholders' Equity	382	324	451	414	327	400	601	534	519	514
Total Liabilities	19	23	25	25	30	94	45	55	58	63
Total Current Liabilities	18	23	25	24	30	94	40	48	51	56
Accounts Payable	3.97	4.66	4.57	3.39	4.78	6.44	3.02	2.54	5.09	5.78
Accrued Expenses	14	18	20	21	25	87	35	44	44	48
Current Deferred Revenue	-	-	-	-	-	-	1.46	1.64	1.85	2.32
Other Current Liabilities	0.46	0.42	0.43	0.44	0.30	0.19	0.08	0.06	0.15	0.16
Total Noncurrent Liabilities	0.51	0.30	0.19	0.08	0.00	0.00	5.60	6.97	6.98	6.45
Noncurrent Deferred Revenue	-	-	-	-	-	-	3.06	3.35	3.37	2.95
Other Noncurrent Operating Liabilities	0.51	0.30	0.19	0.08	-	-	2.54	3.62	3.61	3.49
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	363	300	426	390	297	307	555	480	461	451
Total Preferred & Common Equity	363	300	426	390	297	307	555	480	461	451
Total Common Equity	363	300	426	390	297	307	555	480	461	451
Common Stock	593	612	784	794	818	832	1,044	1,070	1,081	1,091
Retained Earnings	-230	-312	-358	-404	-521	-525	-488	-590	-620	-640
Accumulated Other Comprehensive Income / (Loss)	-0.39	0.07	-0.01	-0.01	-0.01	-0.02	-0.01	-0.05	-0.09	0.07

This table displays calculated financial ratios and metrics derived from Day One Biopharmaceuticals' official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	61,928,939.00	-	-	-	102,675,502.00
DEI Adjusted Shares Outstanding	0.00	0.00	61,928,939.00	-	-	-	102,675,502.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	-2.76	-	-	-	-1.05
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	20.60%
EBITDA Growth	0.00%	-192.87%	-66.20%	-104.56%	-45.36%	-2.16%	36.61%
EBIT Growth	0.00%	-193.91%	-66.06%	-101.94%	-40.25%	-4.85%	40.86%
NOPAT Growth	0.00%	7.53%	-427.81%	-101.96%	-40.27%	-5.44%	41.20%
Net Income Growth	0.00%	-158.14%	-65.94%	-95.43%	-32.87%	49.45%	-12.38%
EPS Growth	0.00%	-244.13%	36.97%	53.03%	-9.22%	56.96%	-1.96%
Operating Cash Flow Growth	0.00%	-198.76%	-259.84%	-126.36%	-33.66%	46.81%	-32.83%
Free Cash Flow Firm Growth	0.00%	0.00%	-269.31%	31.39%	-40.37%	-6.13%	17.13%
Invested Capital Growth	0.00%	0.00%	96.39%	-207.21%	-93.62%	-46.26%	100.17%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	28.65%	18.34%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-18.06%	-9.31%	-8.05%	21.26%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-16.50%	-8.83%	-2.74%	22.87%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-16.46%	-8.86%	-2.75%	22.87%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-14.65%	-8.25%	-13.29%	29.28%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-226.16%	-3.04%	0.00%	28.77%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-17.51%	-25.24%	-4.31%	12.70%	13.26%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-5.33%	11.23%	-0.25%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	9.19%	-24.49%	-892.09%	106.88%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	95.98%	90.70%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-168.05%	-88.33%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-165.65%	-80.76%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-164.72%	-80.77%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-72.81%	-67.85%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	108.09%	98.19%
Interest Burden Percent	113.93%	100.07%	99.99%	96.77%	91.68%	40.89%	85.54%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	88.08%	-62.89%	-46.37%	-55.68%	-22.49%	-22.74%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-241,720.41%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	-45.07%	-23.43%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	-19.92%	-19.68%
Return on Common Equity (ROCE)	0.00%	98.17%	-61.34%	-46.37%	-55.68%	-22.49%	-22.74%
Return on Equity Simple (ROE_SIMPLE)	0.00%	80.88%	-25.88%	-42.82%	-54.52%	-18.99%	0.00%
Net Operating Profit after Tax (NOPAT)	-10	-9.65	-51	-103	-144	-152	-89
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-115.96%	-56.53%
Net Nonoperating Expense Percent (NNEP)	0.00%	-161.09%	-13.36%	-12.56%	-12.61%	12.60%	-3.68%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-30.97%	-41.62%	-30.25%	-20.27%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	4.02%	9.30%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	88.02%	76.23%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	173.61%	93.65%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	261.63%	171.46%
Earnings before Interest and Taxes (EBIT)	-15	-44	-73	-147	-206	-216	-128
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-15	-44	-73	-148	-216	-220	-140
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	3.71	4.77	3.67	2.54	2.17
Price to Tangible Book Value (P/TBV)	0.00	0.00	3.71	4.77	3.67	2.62	2.26
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	9.74	6.05
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	10,526.99
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	5.69	3.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	1.48	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	0.85	-1.41	-1.02	-1.04	-1.06	-1.03
Leverage Ratio	0.00	-0.92	1.45	1.04	1.07	1.13	1.16
Compound Leverage Factor	0.00	-0.92	1.45	1.01	0.98	0.46	0.99
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	-11.46%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	111.46%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	39.86	71.91	54.46	23.43	8.26	7.27
Noncontrolling Interest Sharing Ratio	0.00%	-11.46%	2.46%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	22.58	33.43	20.94	12.72	7.66	8.02
Quick Ratio	0.00	21.91	32.84	20.60	12.42	7.43	7.73
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	83	-140	-96	-135	-143	-118
Operating Cash Flow to CapEx	0.00%	-14,661.96%	0.00%	-422,592.31%	-65,559.38%	0.00%	-36,026.74%
Free Cash Flow to Firm to Interest Expense	0.00	2,752.79	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-2.17	-449.63	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-2.17	-452.70	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.27	0.29
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	7.79
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	3.05
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	105.22	71.56
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	1.81	4.21
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	46.85
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	119.65
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	201.83	86.76
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	-201.83	79.75
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	-92	-3.33	-10	-20	-29	0.05
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	-5.38	-10.94
Increase / (Decrease) in Invested Capital	0.00	-92	89	-6.90	-9.58	-9.16	29
Enterprise Value (EV)	0.00	122	759	1,241	904	746	516
Market Capitalization	160	160	1,044	1,583	1,271	1,278	957
Book Value per Share	$0.00	($10.03)	$4.54	$4.51	$3.98	$4.99	$4.30
Tangible Book Value per Share	$0.00	($10.03)	$4.54	$4.51	$3.98	$4.83	$4.12
Total Capital	0.00	-50	281	332	347	503	441
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-44	-284	-342	-366	-532	-441
Capital Expenditures (CapEx)	0.00	0.09	0.00	0.03	0.22	-106	0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-0.65	-3.60	-11	-21	-43	-17
Debt-free Net Working Capital (DFNWC)	0.00	43	281	331	346	489	425
Net Working Capital (NWC)	0.00	43	281	331	346	489	425
Net Nonoperating Expense (NNE)	6.55	34	22	39	45	-57	18
Net Nonoperating Obligations (NNO)	0.00	-42	-284	-342	-366	-532	-441
Total Depreciation and Amortization (D&A)	0.00	0.16	0.20	-1.50	-9.70	-4.36	-12
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	-32.66%	-10.45%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	372.73%	268.41%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	372.73%	268.41%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($4.62)	($2.17)	($2.37)	($1.02)	($1.04)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	61.95M	65.47M	79.77M	93.23M	103.21M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($4.62)	($2.17)	($2.37)	($1.02)	($1.04)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	61.95M	65.47M	79.77M	93.23M	103.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($4.62)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	36.96M	73.59M	87.38M	101.35M	103.30M
Normalized Net Operating Profit after Tax (NOPAT)	-10	-9.65	-51	-103	-144	-152	-89
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-115.96%	-56.53%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-67.36%	-69.10%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	-7.18	-1,460.43	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-5.02	-321.58	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-7.18	-1,463.50	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-5.02	-324.65	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Day One Biopharmaceuticals' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	202,709,032.00	101,362,468.00	102,431,933.00	102,675,502.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	202,709,032.00	101,362,468.00	102,431,933.00	102,675,502.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-0.18	-0.30	-0.19	-0.21
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	313.92%	-57.56%	83.92%
EBITDA Growth	-48.79%	-36.59%	-36.69%	-46.55%	-111.82%	155.94%	-10.44%	34.59%	66.89%	-190.96%	56.02%
EBIT Growth	-34.18%	-29.61%	-39.16%	-45.61%	-133.04%	159.94%	-9.70%	38.47%	69.52%	-178.76%	58.03%
NOPAT Growth	-34.14%	-29.57%	-39.24%	-45.60%	-133.09%	184.32%	-9.77%	38.49%	69.54%	-155.92%	57.97%
Net Income Growth	-25.55%	-22.11%	-35.91%	-47.22%	90.39%	180.25%	-20.55%	42.33%	-588.04%	-153.26%	67.62%
EPS Growth	-1.67%	-1.89%	-12.50%	-22.03%	91.80%	170.37%	0.00%	51.39%	-480.00%	-150.00%	66.67%
Operating Cash Flow Growth	-42.45%	-59.66%	-17.17%	-91.38%	-15.78%	236.93%	27.47%	-18.64%	49.51%	-111.44%	52.85%
Free Cash Flow Firm Growth	-11.06%	-95.85%	-39.38%	182.15%	-91.66%	155.38%	-13.98%	-120.25%	-108.54%	-210.45%	-31.91%
Invested Capital Growth	-297.54%	-41.24%	-93.62%	-106.99%	-228.33%	81.65%	-46.26%	130.47%	113.99%	75.62%	100.17%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	1,044.54%	-68.85%	5.32%	10.23%	17.36%	34.99%
EBITDA Q/Q Growth	-17.40%	0.83%	-12.97%	-14.34%	-69.68%	126.19%	-323.02%	34.01%	14.10%	28.05%	-7.83%
EBIT Q/Q Growth	-7.44%	-4.41%	-15.70%	-12.16%	-71.94%	126.85%	-311.76%	37.07%	14.84%	30.60%	-12.83%
NOPAT Q/Q Growth	-7.41%	-4.43%	-15.71%	-12.18%	-71.95%	137.78%	-250.64%	37.14%	14.84%	30.66%	-13.22%
Net Income Q/Q Growth	-8.19%	-0.63%	-18.12%	-14.49%	92.94%	940.41%	-277.43%	45.22%	15.76%	34.94%	-7.87%
EPS Q/Q Growth	-3.39%	11.48%	-16.67%	-14.29%	93.06%	860.00%	-265.79%	44.44%	17.14%	34.48%	-10.53%
Operating Cash Flow Q/Q Growth	-63.29%	12.65%	-11.62%	-20.20%	1.21%	203.31%	-159.13%	-96.60%	57.95%	76.60%	-143.74%
Free Cash Flow Firm Q/Q Growth	93.56%	-43.31%	-2.31%	970.17%	-115.02%	141.41%	-310.56%	-54.62%	-54.68%	78.07%	-151.46%
Invested Capital Q/Q Growth	-105.52%	5.45%	-24.49%	-7.56%	-159.34%	94.72%	-892.09%	122.41%	19.09%	-109.21%	106.88%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	91.37%	98.30%	89.79%	90.62%	100.00%	100.00%	77.98%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	-1,407.54%	32.21%	-230.61%	-144.49%	-112.60%	-69.03%	-55.14%
Operating Margin	0.00%	0.00%	0.00%	0.00%	-1,401.45%	31.61%	-223.68%	-133.50%	-103.14%	-60.94%	-51.12%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	-1,401.57%	32.88%	-223.54%	-133.58%	-103.20%	-61.03%	-51.01%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	-53.80%	39.50%	-224.99%	-117.02%	-89.42%	-49.57%	-39.61%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	154.36%	102.44%	110.93%	100.00%	100.00%	100.00%	91.50%
Interest Burden Percent	93.09%	89.71%	91.59%	93.46%	2.49%	117.26%	90.73%	87.60%	86.65%	81.23%	84.87%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	-2.44%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-40.69%	-46.37%	-55.68%	-69.97%	-45.71%	-17.84%	-22.49%	-17.80%	-24.75%	-30.16%	-22.74%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,493.78%	-1,826.40%	0.00%	-241,720.41%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	-26.98%	6.61%	-61.16%	-50.24%	-42.12%	-14.64%	-14.80%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	-1.04%	7.94%	-61.55%	-44.01%	-36.50%	-11.89%	-11.49%
Return on Common Equity (ROCE)	-40.69%	-46.37%	-55.68%	-69.97%	-45.71%	-17.84%	-22.49%	-17.80%	-24.75%	-30.16%	-22.74%
Return on Equity Simple (ROE_SIMPLE)	-39.00%	-44.79%	0.00%	-70.39%	-54.60%	-15.18%	0.00%	-14.41%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-34	-36	-42	-47	-80	30	-46	-29	-24	-17	-19
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-981.02%	32.38%	-156.57%	-93.45%	-72.20%	-42.66%	-35.78%
Net Nonoperating Expense Percent (NNEP)	-2.72%	-2.60%	-3.63%	-9.99%	18.87%	1.39%	-4.45%	-1.83%	-1.43%	-0.54%	-0.42%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-12.02%	-	-	-	-9.10%	-6.00%	-5.31%	-3.77%	-4.36%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	8.63%	1.70%	10.21%	9.38%	0.00%	0.00%	22.02%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	368.48%	30.90%	101.80%	95.33%	85.43%	70.73%	63.57%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	1,124.34%	35.80%	211.66%	128.80%	106.61%	78.95%	76.23%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	1,492.82%	66.70%	313.47%	224.13%	203.14%	160.94%	129.09%
Earnings before Interest and Taxes (EBIT)	-49	-51	-60	-67	-115	31	-65	-41	-35	-24	-27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-54	-54	-61	-68	-115	30	-67	-44	-38	-27	-30
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.06	2.74	3.67	4.84	3.93	2.20	2.54	1.68	1.43	1.60	2.17
Price to Tangible Book Value (P/TBV)	2.06	2.74	3.67	4.84	4.15	2.27	2.62	1.75	1.49	1.67	2.26
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	147.00	11.99	9.74	4.96	3.51	5.40	6.05
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	50.94	26.61	0.00	10,526.99
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	102.83	6.51	5.69	2.04	1.10	2.02	3.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	6.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.03	-1.04	-1.04	-0.53	-1.10	-1.02	-1.06	-1.02	-1.06	-1.00	-1.03
Leverage Ratio	1.05	1.06	1.07	1.09	1.16	1.07	1.13	1.11	1.20	1.11	1.16
Compound Leverage Factor	0.97	0.95	0.98	1.02	0.03	1.26	1.02	0.97	1.04	0.90	0.98
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	21.00	25.43	24.71	27.09	5.82	16.46	9.11	8.33	6.28	6.26	7.93
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	18.35	16.89	12.72	10.93	4.09	14.62	7.66	10.62	9.65	8.68	8.02
Quick Ratio	18.07	16.57	12.42	10.66	3.96	14.27	7.43	10.26	9.23	8.29	7.73
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-22	-31	-32	279	-42	17	-37	-57	-87	-19	-48
Operating Cash Flow to CapEx	-28,477.85%	-90,400.00%	-517,150.00%	0.00%	-188,957.69%	7,010.08%	-2,114.73%	-18,611.04%	-826,866.67%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.02	0.20	0.27	0.38	0.41	0.24	0.29
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.03	10.53	7.79
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.44	1.34	3.05
Fixed Asset Turnover	0.00	0.00	0.00	0.00	43.23	182.55	105.22	120.25	149.33	85.39	71.56
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.13	0.72	1.81	2.23	1.42	1.49	4.21
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	28.02	34.67	46.85
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	149.66	271.99	119.65
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	2,841.79	509.12	201.83	163.65	257.87	244.19	86.76
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	-2,841.79	-509.12	-201.83	-163.65	-80.19	62.46	79.75
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-17	-16	-20	-21	-55	-2.92	-29	6.49	7.73	-0.71	0.05
Invested Capital Turnover	0.00	0.00	0.00	0.00	-0.23	-10.83	-5.38	-21.86	-7.90	-73.61	-10.94
Increase / (Decrease) in Invested Capital	-13	-4.65	-9.58	-326	-38	13	-9.16	28	63	2.21	29
Enterprise Value (EV)	436	662	904	1,120	842	664	746	331	206	271	516
Market Capitalization	878	1,067	1,271	1,438	1,204	1,223	1,278	804	659	722	957
Book Value per Share	$5.79	$4.48	$3.98	$3.42	$3.51	$6.33	$4.99	$4.73	$4.55	$4.40	$4.30
Tangible Book Value per Share	$5.79	$4.48	$3.98	$3.42	$3.32	$6.14	$4.83	$4.53	$4.35	$4.22	$4.12
Total Capital	426	390	347	297	307	555	503	480	461	451	441
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-443	-406	-366	-318	-362	-558	-532	-473	-453	-452	-441
Capital Expenditures (CapEx)	0.15	0.04	0.01	0.00	0.03	0.72	1.42	0.32	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	-17	-21	-22	-72	-17	-43	-12	-9.90	-18	-17
Debt-free Net Working Capital (DFNWC)	425	389	346	296	289	541	489	461	443	434	425
Net Working Capital (NWC)	425	389	346	296	289	541	489	461	443	434	425
Net Nonoperating Expense (NNE)	11	10	13	16	-76	-6.68	20	7.25	5.84	2.75	2.06
Net Nonoperating Obligations (NNO)	-443	-406	-366	-318	-362	-558	-532	-473	-453	-452	-441
Total Depreciation and Amortization (D&A)	-5.17	-2.55	-1.47	-1.18	-0.49	-0.63	-2.06	-3.36	-3.19	-3.19	-2.22
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	-883.96%	-16.80%	-32.66%	-7.56%	-5.27%	-13.52%	-10.45%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	3,533.35%	530.88%	372.73%	284.56%	236.20%	324.31%	268.41%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	3,533.35%	530.88%	372.73%	284.56%	236.20%	324.31%	268.41%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.61)	($0.54)	($0.63)	($0.72)	($0.05)	$0.38	($0.63)	($0.35)	($0.29)	($0.19)	($0.21)
Adjusted Weighted Average Basic Shares Outstanding	74.96M	85.95M	79.77M	86.68M	87.12M	96.62M	93.23M	102.71M	103.07M	103.38M	103.21M
Adjusted Diluted Earnings per Share	($0.61)	($0.54)	($0.63)	($0.72)	($0.05)	$0.38	($0.63)	($0.35)	($0.29)	($0.19)	($0.21)
Adjusted Weighted Average Diluted Shares Outstanding	74.96M	85.95M	79.77M	86.68M	87.12M	96.94M	93.23M	102.71M	103.07M	103.38M	103.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	86.97M	87.04M	87.38M	87.39M	87.76M	100.85M	101.35M	101.36M	102.43M	102.68M	103.30M
Normalized Net Operating Profit after Tax (NOPAT)	-34	-36	-42	-47	-80	21	-46	-29	-24	-17	-19
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-981.02%	22.13%	-156.57%	-93.45%	-72.20%	-42.66%	-35.78%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	-34.85%	38.56%	-202.82%	-117.02%	-89.42%	-49.57%	-43.29%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Below are the key takeaways from Day One Biopharmaceuticals (DAWN) latest quarterly results and the four-year trend, focusing on the most relevant items for retail investors. Items are grouped with positive items first, then neutral, then negative.

Revenue is rising in 2025, climbing from about $30.8M in Q1 2025 to $53.7M in Q4 2025, signaling topline growth.
Gross margin remains strong in late 2025 (Q4 2025 gross profit roughly $41.9M on $53.7M revenue, about 78% margin), with Q3 2025 showing essentially no cost of revenue and a near-total gross margin.
The company holds a substantial liquidity cushion, including around $408.3M in short-term investments (as of Q3 2025) and a rising cash balance (approximately $33.4M in Q1 2025 to $43.3M in Q3 2025).
Cash inflows from investing activities were large in Q4 2025 (net inflow around $167.5M from sale/maturity of investments), helping improve overall cash position.
Equity financing contributed small but persistent cash receipts in multiple quarters, providing modest liquidity headroom (examples include small common equity issuances in 2024–2025).
The company incurs high R&D and SG&A costs (Q4 2025: SG&A ≈ $34.15M and R&D ≈ $40.95M), which, along with total operating expenses around $69.35M, is typical for a biotech at a development stage but pressures profitability.
Net income remains negative across 2025, with Q4 2025 net income about -$21.28M and prior quarters also reporting losses, indicating profitability remains a distant goal.
Earnings per share are negative (for example, Q4 2025 basic and diluted EPS ≈ -$0.21) and shares outstanding are substantial, highlighting ongoing dilution risk if new financing is pursued through equity.
Weighted-average shares (basic and diluted) are high and rising, which can affect per-share metrics and investor perception as the company continues to burn cash while scaling topline.
Operating cash flow from continuing operations is negative in every 2025 quarter, signaling ongoing cash burn despite topline growth (e.g., Q4 2025 OCF ≈ -$14.15M).

05/24/26 09:56 PM ETAI Generated. May Contain Errors.

Day One Biopharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Day One Biopharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Day One Biopharmaceuticals' net income appears to be on a downward trend, with a most recent value of $0.00 in 2025, falling from -$16.98 million in 2019. The previous period was $0.00 in 2024. See Day One Biopharmaceuticals' forecast for analyst expectations on what's next for the company.

Day One Biopharmaceuticals' total operating income in 2025 was $0.00, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $0.00

Over the last 6 years, Day One Biopharmaceuticals' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Day One Biopharmaceuticals' total liabilities were at $66.67 million at the end of 2025, a 16.7% decrease from 2024, and a 2,930.2% increase since 2020.

In the past 5 years, Day One Biopharmaceuticals' cash and equivalents has ranged from $43.73 million in 2020 to $284.31 million in 2021, and is currently $197.08 million as of their latest financial filing in 2025.

Over the last 6 years, Day One Biopharmaceuticals' book value per share changed from 0.00 in 2019 to 4.30 in 2025, a change of 429.7%.

Related Companies

Financial statements for NASDAQ:DAWN last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Day One Biopharmaceuticals (DAWN) Financials

Financials Breakdown Chart

Key Financial Trends

Day One Biopharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Day One Biopharmaceuticals (DAWN) Financials

Annual Income Statements for Day One Biopharmaceuticals

Quarterly Income Statements for Day One Biopharmaceuticals

Annual Cash Flow Statements for Day One Biopharmaceuticals

Quarterly Cash Flow Statements for Day One Biopharmaceuticals

Annual Balance Sheets for Day One Biopharmaceuticals

Quarterly Balance Sheets for Day One Biopharmaceuticals

Annual Metrics And Ratios for Day One Biopharmaceuticals

Quarterly Metrics And Ratios for Day One Biopharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Day One Biopharmaceuticals Financials - Frequently Asked Questions

When does Day One Biopharmaceuticals' fiscal year end?

How has Day One Biopharmaceuticals' net income changed over the last 6 years?

What is Day One Biopharmaceuticals' operating income?

How has Day One Biopharmaceuticals' revenue changed over the last 6 years?

How much debt does Day One Biopharmaceuticals have?

How much cash does Day One Biopharmaceuticals have?

How has Day One Biopharmaceuticals' book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools